Eli Lilly and Company (ETR:LLY)
Germany · Delayed Price · Currency is EUR | Market Cap | 818.74B +36.8% |
| Revenue (ttm) | 62.66B +47.4% |
| Net Income | 21.92B +127.6% |
| EPS | 24.42 +129.1% |
| Shares Out | n/a |
| PE Ratio | 37.35 |
| Forward PE | 28.54 |
| Dividend | 5.52 (0.60%) |
| Ex-Dividend Date | May 15, 2026 |
| Volume | 1,516 |
| Average Volume | 1,790 |
| Open | 901.60 |
| Previous Close | 893.90 |
| Day's Range | 898.30 - 921.00 |
| 52-Week Range | 535.80 - 971.10 |
| Beta | 0.48 |
| RSI | 68.28 |
| Earnings Date | Apr 30, 2026 |
About Eli Lilly and Company
Eli Lilly and Company discovers, develops, manufactures, and markets human pharmaceutical products in the United States, Europe, China, Japan, and internationally. The company offers cardiometabolic health products, including Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provi... [Read more]
Financial Performance
In 2025, Eli Lilly and Company's revenue was $65.18 billion, an increase of 44.70% compared to the previous year's $45.04 billion. Earnings were $20.64 billion, an increase of 94.90%.
Financial numbers in USD Financial StatementsNews
Studies suggest Ozempic, Mounjaro may slow tumor progression, WSJ reports
New studies suggest GLP-1 drugs such as Ozempic and Mounjaro, developed by Novo Nordisk (NVO) and Eli Lilly (LLY), may significantly improve cancer outcomes by reducing tumor progression, lowering mor...
Eli Lilly’s (LLY) Next-Generation Weight-Loss Drug Clears Big Hurdle
The company has a growing number of obesity medications.
Lilly to showcase oncology portfolio across tumor types and treatment modalities at the 2026 American Society of Clinical Oncology Annual Meeting
Phase 3 LIBRETTO-432 study evaluating Retevmo (selpercatinib) as adjuvant therapy in RET fusion-positive NSCLC to be featured in the Plenary Session and ASCO press program Investigator-initiated study...
LLY Clears Major Obesity Trial: Get Exposure in THNR
Weight loss drugs have been a big growth area in pharmaceuticals since GLP-1s hit the scene. This booming market has also breathed new life into companies like Eli Lilly (LLY), turning the stock into ...
How High Can Eli Lilly’s Stock (LLY) Price Go?
Eli Lilly stock still has major upside potential, according to one top analyst.
Eli Lilly's New GLP-1 Drug Looks Like a Weight-Loss Powerhouse in New Trial
Eli Lilly's investigational drug, retatrutide, delivered an average 80-week weight loss of 70 pounds at the highest dose.
Eli Lilly’s retatrutide readout strengthens long-term narrative, says Truist
Truist keeps the firm’s Buy rating and a $1,281 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial data in obesity announced this morning, where patients…
Eli Lilly ‘sets new bar’ with retatrutide trial results, says Wolfe Research
Eli Lilly (LLY) reported pivotal phase 3 results for retatrutide showing class-leading weight loss of up to 26.1% at 80 weeks and over 30% at 104 weeks in higher-BMI participants,…
Eli Lilly’s retatrutide Triumph-1 study a ‘clean win’, says RBC Capital
RBC Capital keeps the firm’s Outperform rating and a $1,250 price target on Eli Lilly (LLY). The company’s retatrutide Phase 3 clinical trial showing that the drug meets the primary…
Lilly's new experimental shot produced 28% weight loss
The injection is different than Zepbound and Foundayo. It includes GIP, GLP-1, and glucagon
Eli Lilly's New Weight-Loss Treatment Shows Promising Results
An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.
Eli Lilly reports retatrutide meets primary endpoint in TRIUMPH-1 study
Eli Lilly (LLY) announced topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational GIP, GLP-1, and glucagon triple hormone recepto...
Patients on Lilly's next-gen obesity drug lost 28% of body weight, company says
Eli Lilly said on Thursday that its experimental drug retatrutide helped patients diagnosed with obesity lose more than 28% of their weight over a year and a half in a key trial that helps pave the w...
Eli Lilly says next-generation weight loss drug clears crucial obesity trial
Eli Lilly said its next-generation drug cleared a crucial late-stage trial in patients with obesity, delivering significant weight loss across doses. The results bring Lilly one step closer to filing...
Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
In TRIUMPH-1, participants on 12 mg retatrutide lost an average of 70.3 lbs (28.3%) over 80 weeks with 45.3% of participants achieving ≥ 30% weight loss, a level long associated with bariatric surgery...
Focus: Lower cost Novo, Lilly weight-loss pills draw patients from compounded drugs, doctors say
Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nin...
From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook
Shares of Eli Lilly and Company NYSE: LLY, the world's most valuable pharmaceutical stock, started 2026 in a bad way. Near the end of April, LLY shares had fallen as much as 20%.
Eli Lilly accuses church bishops, businessmen of fraud in Trulicity drug rebate scheme
Eli Lilly has disclosed in a civil lawsuit filed in federal court on Tuesday that a rebate fraud scheme cost it more than $200 million. The company alleges several bishops and a leader of the Church o...
Eli Lilly (LLY) Acquires Engage Biologics for $202 Million
The pharma giant is strengthening its drug pipeline.
Eli Lilly acquires Engage Biologics for up to $202M in cash
Engage Biologics announced that it has been acquired by Eli Lilly (LLY). Engage is developing the Tethosome platform, a non-viral DNA delivery system “designed to overcome key limitations in DNA…
President Trump Bought Eli Lilly Stock (LLY) as Government Approved Weight-Loss Pill
The purchase has raised ethical questions in Washington, D.C.
PFE, NVO, LLY: Pharma Stocks Drop as TrumpRx Set for ‘Dramatic Expansion’
Shares in drugmakers Pfizer ($PFE), Eli Lilly ($LLY), and Novo Nordisk ($NVO) edged lower on Monday afternoon after CNBC’s Megan Cassella revealed that President Donald Trump is set to announce…
Eli Lilly (LLY) Dealt Blow as U.S. Supreme Court Refuses to Hear Whistleblower Law Challenge
The pharma company’s arguments have failed to sway the courts.
Lilly to participate in Bernstein's 42nd Annual Strategic Decisions Conference
INDIANAPOLIS, May 18, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in Bernstein's 42nd Annual Strategic Decisions Conference on May 28, 2026. Daniel M. Skovronsky, M.D.